Studies in companion dogs consistently demonstrate antitumor activity utilizing CPMV (MIE-201) alone or in combination with standard therapies against naturally occurring cancers. Data to date demonstrate similar effects as those observed in preclinical tumor models evaluating CPMV. These studies provide valuable proof of concept data regarding the consistency of CPMV's immune stimulation and antitumor effects across species. Additionally, insights into dosing amount and frequency, combined with immune modulating details available from biopsies of treated animals could help to inform and support the design of human clinical trials currently in planning stages. We are also evaluating regulatory requirements regarding canine oncology therapeutics which may provide a separate and expedited path toward the commercialization of our technology.

​​Activity in multiple tumor types​

• Melanoma​

• Mammary​

• Ameloblastoma​

• Carcinoma

​​

Treatment regimens​

• Intratumoral single agent CPMV​

• Combination with radiation

• Combination with hyperthermia​

• Combination with chemotherapies​

Observations​​

• Single agent anti-tumor activity​​

• Combination treatment activity​​

• Increased anti-tumor immune cell infiltrate in tumors​​

• Systemic anti-tumor responses (abscopal effect observed)

Observations

•All MIE-201 treated animals were tumor free, either alive or died of unrelated causes

•Significant increase in immune cell infiltration of tumors receiving radiation + MIE-201